Physician profile
Caryn Borger
NPI 1669569414
$67,698.94
in general payments reported to CMS, 2019-2025
45 companies · $3,265 in 2025
The $3,265 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $14K · 2021: $3,671 · 2022: $21K · 2023: $3,155 · 2024: $3,242 · 2025: $3,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Gift: $59.40 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,078.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Gift | $59.40 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46,772.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $12,704.51 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $1,459.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amneal Pharmaceuticals LLC | $779.53 | 2019-2025 | Unithroid |
| Amgen INC. | $678.64 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $566.45 | 2019-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $421.88 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $381.97 | 2022-2025 | |
| Pfizer INC. | $320.61 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $311.93 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $288.06 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $282.75 | 2020-2025 | Korlym |
| Insulet Corporation | $262.19 | 2019-2025 | Omnipod |
| Dexcom, INC. | $246.61 | 2021-2024 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Borger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.